전립선암에 대한 사이버나이프 방사선 치료 초기경험
Early Experience of Prostate Cancer Treated with CyberKnifeTM Radiotherapy
현재호, 박병훈, 구대용, 김강섭, 송기학, 정원규, 한동석, 김진범, 장영섭,
소속 상세정보
현재호 ( Hyun Jai-Ho )
건양대학교 의과대학 비뇨기과학교실
박병훈 ( Park Byoung-Hun )
건양대학교 의과대학 비뇨기과학교실
구대용 ( Koo Dae-Yong )
충남대학교 의과대학 비뇨기과학교실
김강섭 ( Kim Kang-Seop )
충남대학교 의과대학 비뇨기과학교실
송기학 ( Song Ki-Hak )
충남대학교 의과대학 비뇨기과학교실
정원규 ( Chung Weon-Kuu )
건양대학교 의과대학 방사선종양학교실
한동석 ( Han Dong-Seok )
건양대학교 의과대학 비뇨기과학교실
김진범 ( Kim Jin-Bum )
건양대학교 의과대학 비뇨기과학교실
장영섭 ( Chang Young-Seop )
건양대학교 의과대학 비뇨기과학교실
KMID : 0358320090500111066
Abstract
Purpose: We investigated the outcome in patients with prostatic cancer treated by means of CyberKnifeTM radiotherapy.
Materials and Methods : Between July 2007 and April 2009, 16 patients with prostate cancer underwent CyberKnifeTM radiotherapy. The histologic diagnosis was established by transrectal ultrasonography-guided biopsy. Radiotherapy was performed for a dose of 34 Gy at 8.5 Gy per day over 4 to 18 days. Nine patients were treated with hormone therapy. After treatment, prostate-specific antigen (PSA) relapse was evaluated with periodic PSA follow-up.
Results: The numbers of patients in clinical stages T2 and T3 were 13 and 3, respectively. Two patients had lymph node metastasis with no distant metastasis. The numbers of patients with a Gleason grade of 5, 6, 7, 8, and 9 were 1, 5, 4, 3, and 2, respectively. The mean time to PSA nadir and the mean PSA at nadir were 7 months and 0.43 ng/ml, respectively. To date, there has been no biochemical failure or clinical recurrence. No severe complications were observed in any patients; observed minor complications [n (%)] were perianal pain [2 (12.5%)] and defecation discomfort [2 (12.5%)].
Conclusions: Generally good responses were observed in patients treated with CyberKnifeTM radiotherapy for prostate cancer. No severe complications were observed. More patients and a longer follow-up are required for further conclusions.
키워드
Prostatic neoplasms;Prostate-specific antigen
원문 및 링크아웃 정보
등재저널 정보